Papers

3

Total Citations

23

H-Index

2

About

Rosemarie Krupar is a translational immunologist whose research focuses on harnessing the immune system to combat human papillomavirus-associated oropharyngeal cancer (HPVOPC). Her key contributions center on developing and testing live attenuated *Listeria monocytogenes*-based immunotherapies, specifically ADXS11-001, which expresses the HPV E7 antigen to stimulate targeted T cell responses. In a pioneering "window of opportunity" trial, Krupar demonstrated that administering this immunotherapy prior to robotic surgery significantly enhances HPV-specific T cell immunity in patients, a finding published in 2016 that has garnered 19 citations and established a new paradigm for neoadjuvant immunotherapy in head and neck cancers. Her work further explores how this approach reshapes local and peripheral T cell diversity, offering critical insights into the mechanisms of immune activation within the tumor microenvironment. By bridging preclinical promise with clinical application, Krupar has advanced the field of cancer immunotherapy, providing a compelling rationale for combining viral-targeted vaccines with surgical intervention. Her research continues to influence the development of immunotherapeutic strategies for HPV-driven malignancies, underscoring the potential of bacterial-based vaccines to improve outcomes in this rapidly rising cancer type.

Research Focus

Key Achievements

2
H-Index
3
Papers
23
Total Citations
8
Avg Citations/Paper
🏆 Most Cited Paper
Abstract LB-095: HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity
19 citations · 2016
📈 Most Prolific Year: 2016 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Baylor College of Medicine, University Hospital Schleswig-Holstein

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago